Read More

Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.) 

MSSTF

Read More

Hawaiian Electric Industries Announces Appointments Of Paul Ito As CFO Through ~ December 31, 2024, Following Planned Retirement Of Tayne Sekimura; Utility Industry Veteran Scott DeGhetto To Join HEI As CFO Until Ito Resumes Position

HEI Chief Financial Officer Paul Ito to Become CFO of Hawaiian Electric Company Through Approximately December 31, 2024, Following Planned Retirement of Tayne SekimuraUtility Industry Veteran Scott DeGhetto to Join HEI

ALEX

Read More

Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization And Workforce Restructuring; Kinnate Will Implement A Corporate Restructuring By Reducing The Company’s Workforce By ~70%

Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further developmentPlan to file KIN-8741 c-MET inhibitor Investigational New Drug application

KNTE